Bruker Corporation (NASDAQ:BRKR)’s share price shot up 0.2% during trading on Monday after Citigroup raised their price target on the stock from $29.00 to $34.00. Citigroup currently has a neutral rating on the stock. Bruker Corporation traded as high as $35.16 and last traded at $33.27. 440,254 shares changed hands during mid-day trading, a decline of 13% from the average session volume of 505,984 shares. The stock had previously closed at $33.34.

BRKR has been the topic of several other reports. Bank of America Corporation upgraded shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target on the stock in a research note on Friday. BidaskClub downgraded shares of Bruker Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company restated a “hold” rating and issued a $29.00 price target on shares of Bruker Corporation in a research note on Friday. J P Morgan Chase & Co upgraded shares of Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Friday. Finally, Barclays PLC restated an “equal weight” rating and issued a $30.00 price target (up from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $28.58.

In other news, CEO Frank H. Laukien acquired 2,335 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $27.39 per share, with a total value of $63,955.65. Following the completion of the transaction, the chief executive officer now directly owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. Corporate insiders own 35.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Alps Advisors Inc. lifted its position in Bruker Corporation by 0.3% during the second quarter. Alps Advisors Inc. now owns 20,154 shares of the medical research company’s stock worth $581,000 after purchasing an additional 52 shares during the period. Utah Retirement Systems lifted its holdings in shares of Bruker Corporation by 1.1% in the second quarter. Utah Retirement Systems now owns 19,189 shares of the medical research company’s stock worth $553,000 after acquiring an additional 200 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Bruker Corporation by 0.3% in the second quarter. Federated Investors Inc. PA now owns 60,553 shares of the medical research company’s stock worth $1,746,000 after acquiring an additional 204 shares during the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Bruker Corporation by 1.5% in the second quarter. Tudor Investment Corp ET AL now owns 15,980 shares of the medical research company’s stock worth $461,000 after acquiring an additional 242 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in shares of Bruker Corporation by 0.7% in the first quarter. Public Employees Retirement System of Ohio now owns 48,267 shares of the medical research company’s stock worth $1,126,000 after acquiring an additional 312 shares during the last quarter. 65.73% of the stock is owned by institutional investors and hedge funds.

The company has a market capitalization of $5,279.47, a price-to-earnings ratio of 28.50, a P/E/G ratio of 3.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.63 and a quick ratio of 1.61.

Bruker Corporation (NASDAQ:BRKR) last posted its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The firm had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.93%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 earnings per share. analysts anticipate that Bruker Corporation will post 1.17 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Bruker Corporation (BRKR) Shares Up -0.2% Following Analyst Upgrade” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/bruker-corporation-brkr-shares-up-0-2-following-analyst-upgrade/1683433.html.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.